Yet, despite these encouraging findings, calprotectin remains underused in clinical practice, partly due to the limited availability of comparative, real-world longitudinal data across different RA treatment classes, such as inhibitors of tumor necrosis factor-α (TNF-α), Janus kinases (JAK), and interleukin-6 (IL-6). This evidence concerns the gene TNF and rheumatoid arthritis.